Introduction
============

Hepatocellular carcinoma (HCC) is the third-most common cause of cancer mortality worldwide.[@b1-ott-8-3193],[@b2-ott-8-3193] HCC is often diagnosed at an advanced stage, or the patients have advanced liver cirrhosis at the time of diagnosis and are thus considered unsuitable for potentially curative approaches, such as resection, liver transplantation, or other locoregional therapies.[@b3-ott-8-3193] Sorafenib is a molecularly targeted multikinase inhibitor that suppresses both signal transduction of tumor growth and angiogenesis by inhibiting Raf kinase and VEGF- and PDGF-receptor kinase.[@b4-ott-8-3193] Two large-scale Phase III clinical studies -- the SHARP[@b5-ott-8-3193] and Asia-Pacific studies[@b6-ott-8-3193] -- demonstrated that sorafenib significantly prolonged time to progression and improved overall survival in patients with advanced HCC, and confirmed its efficacy in improving the prognosis in these patients as a systemic chemotherapeutic agent. Accordingly, sorafenib has been recognized as the only standard systemic chemotherapeutic agent for patients with advanced HCC for whom resection and local therapy are not indicated.[@b5-ott-8-3193]--[@b7-ott-8-3193] Although treatment with sorafenib shows survival prolongation in advanced HCC patients, the antitumor effect of sorafenib is complete response (CR) or partial response (PR) in only 2.0%--3.3% of advanced HCC patients, and stable disease (SD) in 27.6%--54.0% of those.[@b5-ott-8-3193],[@b6-ott-8-3193] Sorafenib is a safe and effective treatment for patients with advanced HCC;[@b5-ott-8-3193],[@b6-ott-8-3193],[@b8-ott-8-3193],[@b9-ott-8-3193] however, details of its benefits for patients with SD remain to be determined. It also remains obscure which SD patients get a survival benefit from sorafenib.

Accordingly, the present study investigated whether the initial imaging response could be used as a prognostic indicator after administration of sorafenib therapy in HCC patients.

Patients and methods
====================

Patients
--------

Data collected prospectively for a total of 78 patients with advanced HCC consecutively started on sorafenib (Nexavar; Bayer AG, Leverkusen, Germany) therapy at the Department of Hepato-Biliary-Pancreatic Surgery, National Hospital Organization Kyushu Medical Center between July 2009 and December 2011 were reviewed. Inclusion criteria for this study were as follows: HCC was diagnosed either by pathological examination or by the combination of typical radiological findings on dynamic multidetectorrow computed tomography (MDCT) or magnetic resonance imaging (MRI) and elevated alpha-fetoprotein (AFP) serum levels or elevated des-γ-carboxy prothrombin serum levels, according to the American Association for the Study of Liver Diseases;[@b7-ott-8-3193] patients were classified as having advanced HCC if they were not eligible for or had disease progression after surgical or locoregional therapies; Eastern Cooperative Oncology Group performance status score of 0--1; Child--Pugh liver function class A or B (\<7); adequate hepatic function (albumin level \>2.5 g/dL, total bilirubin level \<3.0 mg/dL, and alanine and aspartate aminotransferase levels less than five times the upper limit of normal); dynamic MDCT was obtained at baseline and after 4--6 weeks of sorafenib treatment in order to assess the therapeutic effects. Of 78 patients, 13 discontinued sorafenib treatment before initial radiological response evaluation for adverse events excluded them. Sixty-five patients meeting the inclusion criteria were enrolled. This study was approved by the ethics committee of the National Hospital Organization Kyushu Medical Center and performed in compliance with the Declaration of Helsinki. All patients provided informed consent.

Sorafenib therapy
-----------------

The starting dosage of sorafenib was 800 mg/day orally. However, given the possibility of having to discontinue sorafenib treatment at an early stage due to adverse events, the initial dosage for patients with Child--Pugh B or comorbidities was reduced to 400 mg/day. Moreover, the initial dosage for patients aged ≥80 years, those with a body weight ≤40 kg, or a history of treatment for varices or ascites was set at 200--400 mg/day. Sorafenib therapy was continued until the occurrence of potentially fatal adverse events.

Image-based evaluation of antitumor effects
-------------------------------------------

Dynamic MDCT images or dynamic MRI images were taken at baseline and after 4--6 weeks of sorafenib treatment. Tumor responses were defined as a time-point response 4--6 weeks after sorafenib administration, in accordance with the modified Response Evaluation Criteria in Solid Tumors (RECIST).[@b10-ott-8-3193] A total of five target lesions were assessed in each patient, with a maximum of two lesions per organ. The criteria for determining objective tumor response for target lesions were as follows: CR, disappearance of all target lesions; PR, at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; progressive disease (PD), at least a 20% increase in the sum of diameters of target lesions; and SD, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. However, SD is defined by confirmation of stability at least 4 weeks after the first demonstration of stability. In this study, initial response assessment of neither CR nor PR nor PD was defined as non-PR non-PD. For initial imaging response evaluation, patients were initially divided into four groups according to tumor response: CR, PR, PD, and non-PR non-PD. In this study, the non-PR non-PD patients were further divided into patients with a mild response (MR; −30% to −5%), those with no change (NC; −5% to +5%), and those with mild-PD (MPD; +5% to +20%) as more detailed categorization. Prospectively maintained data of measured value of each tumor in the computed tomography (CT) scan or the MRI at basement and the following evaluations was retrospectively reviewed.

Follow-up
---------

All patients were followed at our outpatient clinic in a standardized manner, including tumor-marker tests every 1--2 months and CT or MRI every 6 weeks until the patient's death or last visit.

Statistics
----------

Statistical analyses were performed using JMP version 11.0 software (SAS Institute Inc, Cary, NC, USA). Categorical variables were analyzed using the *χ*^2^ test or Fisher's exact test, as appropriate. Continuous variables were analyzed using Student's *t*-test or the Mann--Whitney *U*-test, as appropriate. Progression-free survival and overall survival were analyzed using the Kaplan--Meier method, and comparisons between groups were performed using the log-rank test. Multivariate analysis was performed using a Cox proportional-hazard model and the backward-elimination procedure. A *P*-value \<0.05 was taken to indicate a statistically significant difference.

Results
=======

Patient characteristics at baseline
-----------------------------------

[Table 1](#t1-ott-8-3193){ref-type="table"} shows the baseline characteristics of the 65 HCC patients enrolled in this study. The study cohort consisted of 48 males and 17 females, with a mean age of 68.5 years. For tumor condition, 32 (49.2%) HCC patients had extrahepatic spread, eleven (16.9%) had lymph-node metastases, 23 (35.4%) had distant metastasis, and ten (15.4%) had macrovascular invasion. A total of 23 (35.4%) were Barcelona Clinical Liver Cancer (BCLC)-B[@b11-ott-8-3193] and 42 (64.6%) were BCLC-C. All of BCLC-B patients had previously undergone transarterial chemoembolization and were refractory to. As for liver function, most were Child--Pugh A, and ten patients (15.4%) were Child--Pugh B. The starting dosage of sorafenib in this study was 800 mg/day in eleven patients, 400 mg/day in 48 patients, and 200 mg/day in five patients.

Tumor response at initial imaging evaluation
--------------------------------------------

Of the 65 patients, one (1.5%) exhibited PR, 46 (70.8%) exhibited non-PR non-PD, and 18 (27.7%) exhibited PD at the initial evaluation. The median survival time in the 65 patients was 15.6 months, and the time to progression was 5.7 months. The median survival time in BCLC-B and BCLC-C patients was 24.0 and 14.0 months, respectively (*P*=0.046). The median survival time in non-PR non-PD and PD patients was 17.2 and 7.2 months, respectively (*P*\<0.01) ([Figure 1](#f1-ott-8-3193){ref-type="fig"}), and the median time to progression in non-PR non-PD and PD patients was 8.1 and 1.8 months, respectively (*P*\<0.001).

Minute tumor response (MR, NC, and MPD) at initial imaging evaluation in the non-PR non-PD patients
---------------------------------------------------------------------------------------------------

Patients exhibiting non-PR non-PD are generally assumed to be the most important group in terms of improving survival. To clarify which non-PR non-PD patients were endowed a survival benefit by sorafenib, the non-PR non-PD patients were further divided into three groups (MR, NC, and MPD) according to the shrinkage/progression ratio at the initial imaging response. Of the 46 non-PR non-PD patients, 43 had target lesions, while three did not. Among 43 non-PR non-PD patients, ten (23.3%) exhibited MR, 14 (32.6%) exhibited NC, and 19 (44.2%) exhibited MPD. Average shrinkage:progression ratios at initial imaging response among MR, NC, and MPD patients were −12.8%±5.5%, 1.5%±2.9%, and 11.5%±3.8%, respectively (*P*\<0.001) ([Figure 2](#f2-ott-8-3193){ref-type="fig"}). Characteristics of the three groups at baseline are shown in [Table 2](#t2-ott-8-3193){ref-type="table"}.

Cumulative overall survival and time to progression in the non-PR non-PD patients
---------------------------------------------------------------------------------

As shown in [Figure 3](#f3-ott-8-3193){ref-type="fig"}, the median survival time of NC patients of 31.9 months was superior to that of MPD patients of 17.1 months (*P*=0.001). The time to progression of NC patients of 14.8 months was superior to that of MPD of 5.3 months (*P*\<0.001) ([Figure 4](#f4-ott-8-3193){ref-type="fig"}). There was no statistical difference in overall survival or progression-free survival between MR and NC patients. These findings indicate that the clinical meaning of MR is similar to that of no change.

Therefore, the NC+MR patients were compared with the MPD patients. In patient characteristics between these two groups, des-γ-carboxy prothrombin (≥1,000 mAu/mL) was significantly different (*P*=0.02) ([Table 3](#t3-ott-8-3193){ref-type="table"}). The median survival time in the former group of 31.9 months was superior to that in MPD patients of 17.1 months (*P*\<0.001) ([Figure 5](#f5-ott-8-3193){ref-type="fig"}). The time to progression in the MR+NC patients of 15.0 months was superior to that in MPD patients of 5.3 months (*P*\<0.01) ([Figure 6](#f6-ott-8-3193){ref-type="fig"}). These findings indicate that MR and NC effects implied long survival and a long SD effect at the initial radiological evaluation in SD patients.

Prediction of survival in the SD patients
-----------------------------------------

In univariate analysis of prognostic factors by multivariate Cox's proportional-hazard modeling of overall survival, etiology, the Child--Pugh status, and initial imaging response were significant indicators. In multivariate analysis, etiology (hepatitis C virus) (hazard ratio 0.122, 95% confidence interval 0.029--1.478; *P*\<0.01) and initial imaging response (MR+NC) (hazard ratio 0.354, 95% confidence interval 0.117--0.987; *P*=0.047) were identified as an independent prognostic factor ([Table 4](#t4-ott-8-3193){ref-type="table"}).

Discussion
==========

The present study sought to clarify which patients showed a longer-term SD effect among the advanced HCC patients exhibiting non-PR non-PD by sorafenib treatment. Comparison of progression-free survival or overall survival in groups with mildly different initial imaging results revealed that more detailed categorization of the progression or shrinkage ratio at the initial imaging response evaluation may be a useful marker for predicting sorafenib-treatment outcomes in HCC patients.

Non-PR non-PD refers to a relatively wide range -- from a 30% decrease to a 20% increase -- in the sum of diameters of target lesions. As for sorafenib treatment for advanced HCC patients, although only a few patients exhibit CR or PR and 48%--71% patients exhibit SD,[@b5-ott-8-3193],[@b6-ott-8-3193],[@b12-ott-8-3193] sorafenib treatment prolonged the survival of advanced HCC patients. This suggests that successful sorafenib treatment was characterized by a long-SD effect. The present study revealed that 46 patients (70.6%) exhibited non-PR non-SD at the initial radiological evaluation of tumor response and that the median survival time of 17.2 months in non-PR non-PD patients was significantly superior to that of 7.2 months in PD patients. These findings agreed with those of previous reports. The previous results raised the question of which among the non-PR non-PD patients showed a longer-SD effect; however, that question was not pursued. To clarify which non-PR non-PD patients showed a long-SD effect, the present study focused on tumor shrinkage or progression ratios at the initial radiological evaluation of tumor response in non-PR non-PD patients.

RECIST criteria (version 1.1)[@b13-ott-8-3193] or the modified RECIST assessment[@b10-ott-8-3193] defines the category of SD (non-PR non-PD) as a relatively wide range: between 30% shrinkage and 20% progression. The present study investigated the correlation between more detailed categories of initial radiological response and survival. The non-PR non-PD patients were further divided into three groups (MR, NC, and MPD) as more detailed categorization of the tumor shrinkage/progression ratio. Comparing the times to progression among these groups, that of NC patients was similar to that of MR patients; however, that of MPD patients (5.3 months) were significantly inferior to that of NC patients (14.8 months) (*P*=0.001). The same result was found for overall survival. The median survival time of MPD patients (17.1 months) was significantly inferior to that of NC patients (31.9 months) (*P*\<0.001). These results suggested that radiological progression, even if only slightly progressed, led to poorer prognosis. On the other hand, the median survival time of NC patients was similar to that of MR patients. These results are supported by previous reports[@b5-ott-8-3193],[@b6-ott-8-3193],[@b14-ott-8-3193],[@b15-ott-8-3193] that the significant feature of sorafenib was inhibition of tumor progression. The present study distinctly proved that sorafenib treatment showed disease stabilization for a long period.[@b5-ott-8-3193],[@b6-ott-8-3193],[@b14-ott-8-3193],[@b15-ott-8-3193]

It is quite difficult to predict associated factors for prognosis or tumor response of sorafenib before administration of sorafenib. No molecular biomarker has been found for sorafenib. However, several retrospective studies have reported that a reaction in the early period of administration, such as the appearance of an adverse event[@b16-ott-8-3193]--[@b18-ott-8-3193] or variation of a tumor marker,[@b12-ott-8-3193],[@b19-ott-8-3193],[@b20-ott-8-3193] may be associated with prognosis or response. It has been reported that a severe adverse event was associated with a good prognosis.[@b21-ott-8-3193]

There are several limitations to this study. The first limitation concerns the administration dose of sorafenib. In this study, only 17% of patients underwent sorafenib treatment at the recommended dose of 800 mg/day. Nonetheless, a sorafenib dose of 400 mg/day has previously been shown to have similar efficacy,[@b22-ott-8-3193] and the issue of the administration dose of sorafenib is controversial. In this study, patients with poor liver-reserve function, comorbidities, old age, low body weight, or deterioration of liver function were initiated with a reduced sorafenib dose of 200--400 mg/day, and the sorafenib dose was escalated by tolerability. This method can improve patient tolerance and long-term treatment. The second limitation concerns the variety of tumor conditions. Responses vary according to the location or size of the tumor. However, the location of the tumor did not affect the response to sorafenib of patients in this study (data not shown). The third limitation regards the study design, since our results are based on a retrospectively selected patient analysis. However, the current study was based on prospectively collected data, and during the investigation period, patients were treated using a unified strategy at a single institution with extensive experience caring for HCC patients. A further prospective study is needed to confirm the validity of our results.

Conclusion
==========

This study revealed that more detailed categorization of the progression or shrinkage ratio at the initial imaging response evaluation could be a surrogate marker for the long-term outcome of sorafenib treatment in HCC patients. If the initial imaging response is not progression but stability, sorafenib may result in survival benefit.
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![Kaplan--Meier curve of progression-free survival in MR, NC, and MPD patients.\
**Abbreviations:** MR, mild response; NC, no change; MPD, mild progressive disease.](ott-8-3193Fig4){#f4-ott-8-3193}

![Kaplan--Meier curve of overall survival in MR+NC and MPD patients.\
**Abbreviations:** MR, mild response; NC, no change; MPD, mild progressive disease.](ott-8-3193Fig5){#f5-ott-8-3193}

![Kaplan--Meier curve of progression-free survival in MR+NC and MPD patients.\
**Abbreviations:** MR, mild response; NC, no change; MPD, mild progressive disease.](ott-8-3193Fig6){#f6-ott-8-3193}

###### 

Baseline clinical characteristics of the patients (n=65)

  -------------------------------- ------
  Age, years                       
   Average                         68.5
  Sex                              
   Male                            48
   Female                          17
  Etiology                         
   HBV                             11
   HCV                             45
   NBNC                            9
  Extrahepatic spread              
   Yes                             32
   No                              33
  Distant metastasis               
   Yes                             23
   No                              42
  Lymph-node metastasis            
   Yes                             11
   No                              54
  Macroscopic vascular invasion    
   Yes                             10
   No                              55
  BCLC stage                       
   B                               23
   C                               42
  Child--Pugh                      
   A                               55
   B                               10
  Initial dose of sorafenib (mg)   
   800                             11
   400                             48
   200                             11
  AFP (ng/mL)                      
   ≥200                            14
   \<200                           51
  DCP (mAu/mL)                     
   ≥1,000                          21
   \<1,000                         44
  -------------------------------- ------

**Abbreviations:** AFP, alpha-fetoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, non-HBV non-HCV; BCLC, Barcelona Clinical Liver Cancer; DCP, des-γ-carboxy prothrombin.

###### 

Characteristics at baseline of MR, NC, and MPD in non-PR non-PD patients

  -------------------------------------------------------------------------------------------------
  Variable                                                   MR\          NC\          MPD\
                                                             (n=10)       (n=14)       (n=19)
  ---------------------------------------------------------- ------------ ------------ ------------
  Age                                                                                  

   Average                                                   68.7         67.0         67.7

  Sex                                                                                  

   Male                                                      6            11           15

   Female                                                    4            3            4

  Etiology                                                                             

   HBV                                                       2            2            3

   HCV                                                       6            11           13

   NBNC                                                      2            1            3

  Extrahepatic spread                                                                  

   Yes                                                       7            4            11

   No                                                        3            10           8

  Distant metastasis                                                                   

   Yes                                                       5            2            11

   No                                                        5            12           8

  Distant metastasis                                                                   

   Yes                                                       2            2            4

   No                                                        8            12           15

  Macroscopic vascular invasion                                                        

   Yes                                                       0            2            3

   No                                                        10           12           16

  BCLC stage                                                                           

   B                                                         3            8            7

   C                                                         7            6            12

  Child--Pugh                                                                          

   A                                                         10           12           15

   B                                                         0            2            4

  Initial dose of sorafenib (mg)                                                       

   800                                                       3            3            4

   400                                                       6            11           11

   200                                                       1            0            4

  AFP (ng/mL)                                                                          

   ≥200                                                      1            3            1

   \<200                                                     9            16           13

  DCP (mAu/mL)                                                                         

   ≥1,000                                                    1            7            1

   \<1,000                                                   9            12           13

  Interval for the initial radiological assessment (weeks)                             

   Average range                                             5.8 (4--6)   5.9 (5--6)   5.7 (5--6)
  -------------------------------------------------------------------------------------------------

**Abbreviations:** AFP, alpha-fetoprotein; MR, mild response; NC, no change; MPD, mild progressive disease; PR, partial response; PD, progressive disease; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, non-HBV non-HCV; BCLC, Barcelona Clinical Liver Cancer; DCP, des-γ-carboxy prothrombin.

###### 

Patients characteristics at baseline of MR+NC and MPD patients in non-PR non-PD patients

  --------------------------------------------------------------
  Variable                         MR+NC\   MPD\     *P*-value
                                   (n=24)   (n=19)   
  -------------------------------- -------- -------- -----------
  Age, years                                         

   Average                         67.7     67.7     0.99

  Sex                                                

   Male                            14       15       0.54

   Female                          7        4        

  Etiology                                           

   HBV                             4        3        0.95

   HCV                             17       13       

   NBNC                            3        3        

  Extrahepatic spread                                

   Yes                             11       11       0.43

   No                              13       8        

  Distant metastasis                                 

   Yes                             7        8        0.38

   No                              17       11       

  Lymph-node metastasis                              

   Yes                             4        4        0.74

   No                              20       15       

  Macroscopic vascular invasion                      

   Yes                             2        3        0.41

   No                              22       16       

  BCLC stage                                         

   B                               11       7        0.55

   C                               13       12       

  Child--Pugh                                        

   A                               22       15       0.23

   B                               2        4        

  Initial dose of sorafenib (mg)                     

   800                             6        4        0.26

   400                             17       11       

   200                             1        4        

  AFP (ng/mL)                                        

   ≥200                            2        3        0.45

   \<200                           22       16       

  DCP (mAu/mL)                                       

   ≥1,000                          2        7        0.02

   \<1,000                         22       12       
  --------------------------------------------------------------

**Abbreviations:** AFP, alpha-fetoprotein; MR, mild response; NC, no change; MPD, mild progressive disease; PR, partial response; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, non-HBV non-HCV; BCLC, Barcelona Clinical Liver Cancer; DCP, des-γ-carboxy prothrombin.

###### 

Prognostic factors in non-PR non-PD patients

  Variable                             Univariate analysis     Multivariate analysis                           
  ------------------------------------ ----------------------- ----------------------- ----------------------- --------
  Age (\<70 years)                     2.591 (0.984--7.626)    0.054                   1.154 (0.419--3.536)    0.79
  Sex (male)                           2.005 (0.652--8.718)    0.24                    2.707 (0.773--12.976)   0.13
  Etiology (HCV)                       0.349 (0.131--0.992)    0.048                   0.122 (0.029--0.478)    \<0.01
  Extrahepatic spread (yes)            1.290 (0.492--3.444)    0.60                    --                      --
  Macroscopic vascular invasion (no)   1.810 (0.396--6.215)    0.40                    --                      --
  BCLC (B)                             0.667 (0.229--1.760)    0.42                    --                      --
  Child--Pugh (B)                      3.619 (0.976--11.194)   0.054                   2.394 (0.634--7.581)    0.18
  Initial dose of sorafenib (800 mg)   2.012 (0.714--5.442)    0.18                    2.338 (0.738--7.416)    0.15
  AFP (\<200 ng/mL)                    2.234 (0.455--40.332)   0.38                    --                      --
  DCP (≥1,000 mAu/mL)                  1.435 (0.400--4.134)    0.55                    --                      --
  Initial imaging response (MR+NC)     0.299 (0.100--0.817)    0.019                   0.354 (0.117--0.987)    0.047

**Abbreviations:** AFP, alpha-fetoprotein; PR, partial response; PD, progressive disease; CI, confidence interval; HCV, hepatitis C virus; BCLC, Barcelona Clinical Liver Cancer; DCP, des-γ-carboxy prothrombin; MR, mild response; NC, no change.
